Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Predictive factors and biomarkers of response to antidepressants in major depressive disorder
are scarce. Beta-arrestins are proteins which inhibit G Protein Coupled Receptors and
desensitize serotonergic and dopaminergic receptors. The study hypothesis is that
Beta-arrestins 1 and 2 are predictive factors and biomarkers of response to antidepressants
in major depressive disorder. In a controlled prospective open naturalistic monocentric
3-month study, 60 patients with a major depressive disorder requiring a treatment with
venlafaxine will be included and assessed before treatment, 1 month and 3 months
post-treatment. 20 controlled healthy subjects matched for age and gender will also be
assessed. The Beta-arrestin pathway will be assessed using genetic polymorphisms, Peripheral
Blood Mononuclear Cell measures and functional pathway. Antidepressant response will be
assessed using depression scales, olfaction and memory as surrogate markers of neurogenesis.